APTATARGETS

Focused on therapeutic aptamers, aptaTargets is currently developing ApTOLL, an immune modulator which represents a novel approach to treat ischemic stroke in the acute phase by substantially reducing the brain damage. After the successful development in nonclinical stages and First-in-Human trial (Phase I), company is advancing up to a clinical Proof-of-Concept in patients... aptaTargets - Biopharmaceutical company focused on the development of all types of therapeutic applications based on aptamer technology ... Additionally, aptaTargets aims to study the use of ApTOLL in other indications where TLR4 receptor plays a key role (intracerebral hemorrhage, myocardial infarction, and multiple sclerosis), and to launch other drug development programs with new aptamer drug candidates.

Also known as: AptaTargets SL

Primary location: Madrid Spain